Sildenafil for LVAD support
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether sildenafil (the drug in Viagra) can help reduce blood vessel changes in people with a left ventricular assist device (LVAD). It aims to improve heart-pump function and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You currently have a durable LVAD or are scheduled to have one placed.
- You are able to give your own consent to participate.
- You do not have a pre-existing aortic valve prosthesis or aortic graft.
- You are not allergic to sildenafil (the active ingredient in Viagra).
- You are not taking any nitric oxide donor medications (like nitroglycerin or isosorbide).
- You do not have a history of complete carotid artery blockage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if sildenafil can help people with severe pulmonary hypertension caused by rheumatic valvular heart disease. It aims to see if the drug improves symptoms and heart function.
This trial studies how the drugs sildenafil and pravastatin work in people with a single ventricle heart condition who have had the Fontan surgery and may have related liver problems. The goal is to find the best doses based on liver function.
This study tests a program that provides extra support and care planning for people who have been living with a heart pump (LVAD) for at least a year. The goal is to help you feel better and manage your health.
This trial looks at how well people with advanced heart failure do over the long term after getting a left-ventricular assist device (LVAD). Researchers will check blood and heart tissue samples to learn more about recovery and outcomes.
This trial tests a temporary heart pump to support patients with weak hearts (ejection fraction 35% or less) who need a high-risk stent procedure instead of bypass surgery. The pump may help keep blood flowing during the procedure.
This trial studies whether a heart medicine called ARNI (sacubitril-valsartan) is safe and works well for people who have a durable LVAD and moderate-to-severe heart pumping weakness. It may help improve symptoms and outcomes, while carefully checking side effects in this higher-risk group.
Hear when a new Vascular Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.